Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
<p>Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.</p>